Impax Laboratories (IPXL) Announces Positive Phase II Results of IPX066
More News related to IPXL
- Impax Laboratories Continues Trend of Solid Growth in Revenue, Profit and Earnings for the Third Quarter 2009
- Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
- Impax Laboratories (IPXL) Initiates Challenges to Abbott's Patents in Connection to TRICOR
- Impax Laboratories Confirms Patent Challenge Relating to TRICOR(R) 48mg and 145mg Tablets
- Impax Laboratories (IPXL) Initiates Phase III Trial of IPX066 in Parkinson's
More News related to FDA
- Information Services Group's (III) Connors and Berger Purchase 440K Shares from Former CFO Martell
- Simcere Pharma (SCR) Announces Agreement to Acquire Tianjin Tianda Pharma; To Manufacture Rosuvastatin
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
- Northrop Grumman (NOC) To Sell TASC in $1.65B Cash Transaction
- Ball Corporation (BLL) Acquires Guangdong Jianlibao Group's 65% Interest in JV Metal Beverage Can Plant
Impax Laboratories, Inc. (NASDAQ: IPXL) announced the positive interim results from a recent Phase II trial of its late-stage drug candidate IPX066 were presented at the 13th International Congress of Parkinson's Disease and Movement Disorders in Paris, France.
The interim results demonstrate superior clinical benefit in the duration of PD motor symptom control as compared to conventional carbidopa-levodopa. IPX066 provided more than two additional hours of reduction in motor "off" time during waking hours as well as two to three hours of increasing duration of finger tapping speeds compared to Sinemet(R) (carbidopa-levodopa). In addition to the data presented, IPX066 treated-patients also experienced prolonged improvements in walking speeds as compared to Sinemet(R). The decrease in motor "off" time, and improvements in walking and finger tapping represent clinically significant improvement in PD motor symptom control as compared to Sinemet(R). No unexpected treatment-emergent adverse events were reported in either treatment group. The Phase II study is an active-controlled, multi-center, crossover study in advanced PD patients. The results reported are based on data from the first 13 patients with total enrollment of 27 patients.
More from Release
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
